Conference Coverage
about 5 hours ago
ICYMI: Highlights From SABCS 2025about 6 hours ago
ICYMI: Highlights From COA 20251 day ago
ICYMI: Highlights From ASH 20257 days ago
ICYMI: Highlights From ASCO 202510 days ago
ICYMI: Highlights From AMCP 2025Latest Content
Advertisement
Shorts
0:25
Why Fractionated Radiotherapeutic Dosing May Improve Outcomes in LM Treatment: Andrew Brenner, MD
12 days ago
by
Sabrina McCrear(+1 more)
0:41
How Rhenium Nanoliposomes Target Leptomeningeal Metastases: Andrew Brenner, MD
13 days ago
by
Sabrina McCrear(+1 more)
1:11
Understanding LM Therapy Across Breast Cancer Subtypes: Andrew Brenner, MD
14 days ago
by
Sabrina McCrear(+1 more)
0:58
Changes to USAID Affected Worldwide HIV Response: Antonio Urbina, MD
21 days ago
by
Julia Bonavitacola(+1 more)
1:32
Getting Lenacapavir on Insurance Plans Is Key to Uptake: Antonio Urbina, MD
a month ago
by
Julia Bonavitacola(+1 more)
1:52
DTC Models Offer Promise for Some, but Remain Limited in Scope: Brian Reid, MS
a month ago
by
Brooke McCormick(+1 more)
0:53
Treatments for Symptom-Driven Conditions Are the Best Fit for DTC Models: Jennifer Graff, PharmD
a month ago
by
Brooke McCormick(+1 more)
0:37
Oral Pill Removes Barrier to Cholesterol-Lowering Therapy: Ann Marie Navar, MD, PhD
a month ago
by
Laura Joszt, MA(+1 more)
1:09
Administrative Glitches Could Leave Gaps in Care After Medicaid Work Requirements: Ciara Zachary, PhD, MPH
a month ago
by
Julia Bonavitacola(+1 more)
1:02
Millions Set to Lose Medicaid Despite Some Exceptions to Work Requirements: William Schpero, PhD, MPhil, MPH
a month ago
by
Julia Bonavitacola(+1 more)
Center on Health Equity & Access
Start seeing what truly shapes access and learn how you can redefine the landscape.
Podcasts
Center on Health Equity & Access
Advertisement
All News
Advertisement
Exercise enhances quality of life and sleep for those with ovarian cancer, highlighting the need for further research in supportive care.
The 2025 Community Oncology Conference, hosted by COA, reflected a commitment to patient-centered care, access, and innovation in community oncology.
ASH 2025 reveals groundbreaking trial data on fixed-duration therapies for chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma, enhancing patient outcomes and reducing costs.
The most-viewed content focused on the “One Big Beautiful Bill,” the Most Favored Nation drug policy, and other changes under the Trump administration.
Our top dermatology content of 2025 highlights AI wearables, new biologics, emerging vitiligo treatments, and strategies for rare and complex skin diseases.
ASH 2025 highlighted innovative cancer treatments, including in vivo CAR T therapy and options that enhance quality of life while reducing burdens.
Jonathan Strober, MD, discusses promising results from the VIBRANCE-MG trial, highlighting nipocalimab's safety and efficacy for pediatric myasthenia gravis.
From cutting-edge AI detection tools to rising incidence in younger adults and threats to free screenings, 2025 brought major shifts in the struggle against colorectal cancer.
The top ophthalmology content included FDA approvals, FDA complete response letters, and new associations between cataracts and antioxidant index.
Alopecia areata significantly impacts quality of life, driven by appearance-related anxiety related to where hair loss occurs more than how much is lost.
